First patient dosed in Phase 1/2a study with novel immune rejuvenator, a trispecific antibody-fusion protein Two MDX2004 abstracts accepted for poster presentation at SITC Annual Meeting 2025 WESTON, ...
Pelareorep plus atezolizumab achieves 30% ORR in second-line or later (≥2L) squamous cell anal carcinoma (SCAC) relative to ...
Co., Ltd. ("Fosun Pharma" or "the Group"; SSE: 600196, HKEX: 02196), a leading innovation-driven global healthcare company, announced its financial results for the first three quarters ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback